高级搜索

奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较

刘君, 肖扬, 郭建雄, 魏巍, 黄小红, 张荣侠, 吴宜嘉, 周娟

刘君, 肖扬, 郭建雄, 魏巍, 黄小红, 张荣侠, 吴宜嘉, 周娟. 奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J]. 肿瘤防治研究, 2016, 43(1): 72-77. DOI: 10.3971/j.issn.1000-8578.2016.01.016
引用本文: 刘君, 肖扬, 郭建雄, 魏巍, 黄小红, 张荣侠, 吴宜嘉, 周娟. 奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J]. 肿瘤防治研究, 2016, 43(1): 72-77. DOI: 10.3971/j.issn.1000-8578.2016.01.016
shu
LIU Jun, XIAO Yang, GUO Jianxiong, WEI Wei, HUANG Xiaohong, ZHANG Rongxia, WU Yijia, ZHOU Juan. Clinical Efficacy and Toxicities of Oxaliplatin plus S-1(SOX) and Gemcitabine plus Cisplatin (GP) Regimens on Advanced Triple-negative Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2016, 43(1): 72-77. DOI: 10.3971/j.issn.1000-8578.2016.01.016
Citation: LIU Jun, XIAO Yang, GUO Jianxiong, WEI Wei, HUANG Xiaohong, ZHANG Rongxia, WU Yijia, ZHOU Juan. Clinical Efficacy and Toxicities of Oxaliplatin plus S-1(SOX) and Gemcitabine plus Cisplatin (GP) Regimens on Advanced Triple-negative Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2016, 43(1): 72-77. DOI: 10.3971/j.issn.1000-8578.2016.01.016
shu

奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较

  • 225400 泰兴，泰兴市人民医院肿瘤科

详细信息
    作者简介:

    刘君（1975-），男，硕士，副主任医师，主要从事恶性肿瘤的个体化治疗

  • 中图分类号: R737.9

Clinical Efficacy and Toxicities of Oxaliplatin plus S-1(SOX) and Gemcitabine plus Cisplatin (GP) Regimens on Advanced Triple-negative Breast Cancer Patients

  • Department of Oncology, Taixing People's Hospital, Taixing 225400, China

摘要

    摘要
  • 摘要: 目的 比较奥沙利铂联合替吉奥（SOX方案）和吉西他滨联合顺铂（GP方案）治疗晚期三阴性乳腺癌的疗效和不良反应。方法 晚期三阴性乳腺癌患者随机分别接受多周期SOX方案（SOX 组，63例）和GP方案（GP组，57例）化疗。评价两组疗效和不良反应。结果 SOX组与GP组的总有效率（RR）分别为34.9％与35.1％，疾病控制率（DCR）为68.3％与70.2％，差异无统计学意义（P>0.05）；中位进展时间分别为9.5月与8.1月，差异有统计学意义（P=0.033）；1年生存率分别为69.8％和63.2％，总生存时间（OS）分别为19.5月与18.7月，差异无统计学意义（P=0.554、0.207）。常见的不良反应相似，其中腹泻、肝功能损害、外周神经毒性和手足综合征发生率SOX组明显高于GP组，血小板减少、恶心/呕吐、肾毒性和皮疹发生率GP组明显高于SOX组（P<0.05）。结论 奥沙利铂联合替吉奥、吉西他滨联合顺铂方案治疗晚期三阴性乳腺癌均安全、有效，不良反应耐受。

     

    Abstract: Objective To compare the curative effect and toxicities of oxaliplatin combined with S-1 (SOX) and gemcitabine combined with cisplatin (GP) on advanced triple-negative breast cancer(TNBC) patients. Methods Advanced TNBC patients randomly accepted several cycles of SOX regimen(SOX) (n=63) and GP regimen(GP) (n=57). The efficacy and toxicity were observed between two regimens. Results The total response rates (RR) were 34.9% in SOX group and 35.1% in GP group. The disease control rates(DCR) were 68.3% in SOX group and 70.2% in GP group, respectively (P>0.05); the median time to progression were 9.5 months in SOX group and 8.1 months in GP group (P=0.033); 1-year survival rates were 69.8% and 63.2%, and the overall survival(OS) was 19.5 and 18.7 months, respectively, without any statistically significant difference (P=0.554, 0.207). Adverse reactions were similar between the two groups. The incidence of diarrhea, liver function damage, peripheral nerve toxicity and hand-foot syndrome in SOX group were greater than those in GP group; the incidence of thrombocytopenia, nausea/vomiting, renal toxicity and skin rash in GP group were greater than those in SOX group (P<0.05). Conclusion Both SOX and GP regimens are safe, effective and tolerable in treating advanced TNBC patients.

     

    • HTML全文
    • 参考文献(38)
  • [1] Vrdoljak E, Mise BP, Luki? B, et al. Long-lasting control of triplenegative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine-case report[J]. Onkologie, 2010, 33 (1-2): 53-6.
    [2] Rakha EA, Ellis IO. Triple-negative/basal-like breast carncer: review[J]. Pathology, 2009, 41(1): 40-7.
    [3] Rastelli F, Biancanelli S, Falzetta A, et al. Triple-negative breast cancer:current state of the art[J]. Tumor, 2010, 96(6): 875-88.
    [4] Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J]. J Clin Oncol, 2008, 26 (5): 778-85.
    [5] Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer:molecular profiling and Prognostic impact in adjuvant anthracycline-treated patients[J]. Breast Cancer Res Treat, 2007, 11 1(1): 27-44.
    [6] Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer[J]. Ann Oncol, 2008, 19(11): 18 47-52.
    [7] Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006):a randomised, openlabel, multicentre, phase 3 trial[J]. Lancet Oncol, 2015,16(4): 43 6-46.
    [8] Qin SK, Gong XL. Chemotherapy of advanced gastric carcinoma: current and prospect[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2006, 11 (9): 642-52. [秦叔逵, 龚新雷. 晚期胃癌化疗的现状和新进展 [J] 临床肿瘤学杂志, 2006, 11(9): 642-52.]
    [9] Yuan Q. Clinical observation of 27 cases of nasopharynx cancer treated with HU,FT-207 and CF[J]. Zhongguo Yi Yao Dao Bao, 20 07, 4(20): 54-5. [袁泉. 羟基脲、替加氟及亚叶酸钙治疗27例 晚期鼻咽癌临床观察[J]. 中国医药导报, 2007, 4(20): 54-5.]
    [10] Hara F, Kiyoto S, Takahashi M, et al. Efficacy and safety of S-1 in patients with metastatic breast cancer[J]. Oncology, 2010, 79(3-4): 27 3-7.
    [11] Le Du F, Eckhardt BL, Lim B, et al. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?[J]. Oncotarget, 2015, 6(15): 12890-908.
    [12] Zhang L, Fang C, Xu X, et al. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a metaanalysis[ J] Biomed Res Int, 2015, 2015: 357485.
    [13] Fornier M, Fumoleau P. The paradox of triple-negative breast cancer: novel approaches to treatment[J]. Breast J, 2012, 18(1): 41-51.
    [14] De Laurentiis M, Cianniello D, Caputo R, et al. Treatment triple negative breast cancer:current options and future perspectives[J]. Cancer Treat Rev, 2010, 36(Suppl 3): S80-6.
    [15] Rakha EA, EI-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
    [16] Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in nodenegative breast cancer[J]. BMC Cancer, 2008, 8: 307.
    [17] Dookeran KA, Dignam JJ, Ferrer K, et al. P53 as a marker of prognosis in African-American women with breast cancer[J]. Ann Surg Oncol, 2010, 17(5): 1398-405.
    [18] Chae BJ, Bae JS, Lee A, et al. P53 as a specific prognostic factor in triple-negative breast cancer[J]. Jpn J Clin Oncol, 2009, 39(4): 21 7-24.
    [19] Knappskog S, Berge EO, Chrisanthar R, et al. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo[J]. Mol Oncol, 2015, 9(8): 1553-64.
    [20] Xu ZQ, Zhang Y, Li N, et al. Correlation between curative efficacy of post-operative platinum-based chemotherapy and ERCC1 and P53 protein expression in NSCLC: A retrospective analysis[J]. Zhongguo Xian Dai Yi Sheng, 2010, 48(21): 36-9. [徐志巧, 张燕, 李宁, 等. NSCLC术后铂类药物辅助化疗疗效与ERCC1和P53 蛋白表达的分析[J]. 中国现代医生, 2010, 48(21): 36-9.]
    [21] Hernandez-Aya LF, Chavez-Macgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triplenegative breast cancer[J]. J Clin Oncol, 2011, 29(19): 2628-34.
    [22] Zhou QF, Yue SL,Wu HM, et al. A study on the ER, PR and Her-2 expression statuses between primary lesion and metastatic axillary lymph nodes of TNBC[J]. Shi Yong Zhong Liu Xue Za Zhi, 2013, 27 (1): 54-9. [周秋锋, 岳双磊, 吴红梅, 等. TNBC原发灶与腋淋 巴结转移灶中ER、PR、Her-2的表达变化与预后的相关性[J]. 实用肿瘤学杂志, 2013, 27(1): 54-9.]
    [23] Yadav BS, Sharma SC, Chanana P, et al. Systemic treatment strategies for triple-negative breast cancer[J]. World J Clin Oncol, 20 14, 5(2): 125-33.
    [24] Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage Ⅱ/Ⅲ breast cancer treated with neoadjuvant docetaxel and doxombicin chemotherapy:paradoxical features of the triple negative breast cancer[J]. BMC Cancer, 20 07, 7: 203.
    [25] Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours[J]. Curr Opin Pharmacol, 2005, 5(4): 388-93.
    [26] Uhm JE, Park YH, Yi SY, et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy[J].Int J Cancer, 20 09, 124(6): 1457-62.
    [27] Wei MY, Zhuang YF, Wang WM. Gemcitabine for the treatment of patients with osteosarcoma[J]. Asian Pac J Cancer Prev, 2014, 15 (17): 7159-62.
    [28] Brodowicz T, Kostler WJ, Möslinger R, et al. Single-agent gemeitabine as secondline and third-line treatment in metastatic breast cancer[J]. Breast, 2000, 9(6): 338-42.
    [29] Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer[J]. J Clin Oncol, 20 10, 28(7): 1145-53.
    [30] Kang MF, Jiang HJ, Wang SK, et al. Efficacy of docetaxel combined with oxaliplatin by different administration routes in treatment of anthracycline-resistant metastatic breast cancer[J]. Zhongguo Zhong Liu Lin Chuang Yu Kang Fu, 2005, 12(6): 527-9. [康 马飞, 蒋河君, 王世坤, 等. 多西紫杉醇联合奥沙利铂治疗耐蒽 环类药转移性乳腺癌疗效分析[J]. 中国肿瘤临床与康复, 2005, 12 (6): 527-9.]
    [31] Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J]. Br J Cancer, 2008, 99(4): 584-90.
    [32] Lam SW, de Groot SM, Honkoop AH, et al. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial[J]. Eur J Cancer, 20 14, 50(18): 3077-88.
    [33] Shirasaka T, Tsukuda M, lnuyama Y, et al. New oral anticancer drug,TS-1(S-1)-from bench to clinic[J]. Gan To KagaKu Ryoho, 20 01, 28(6): 855-64.
    [34] Koizumi W, Narahara H, HaraT, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer[J]. Lancet Oncol, 2008, 9(3): 215-21.
    [35] Boku N. Chemotherapy for rnetastatic disease:review from JCOG trials[J]. Int J Clin Oncol, 2008, 13(3): 196-200.
    [36] Shien T, Shimizu C, Akashi-Tanakal S, et al. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients[J]. Jpn J Clin Oncol, 2008, 38(3): 172-5.
    [37] Yamamoto D, Iwase S, Yoshida H, et al. Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN)04-1 trial[J]. Anticancer Res, 20 10, 30(9): 3823-31.
    [38] Fujii K, Kosaka J, Mouri Y, et al. Chemotherapy of a 2-week S-1 administration followed by l-week rest for advanced and metastatic breast cancer[J]. Gan To Kagaku Ryoho, 2011, 38(9): 1467-70.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1600
  • HTML全文浏览量:  416
  • PDF下载量:  671
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-03-23
  • 修回日期:  2015-10-12
  • 刊出日期:  2016-01-24

目录

摘要
HTML全文
    参考文献(38)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：18975031 今日访问：2577

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭